Neurocrine Return On Capital Employed from 2010 to 2025

NBIX Stock  USD 120.18  1.06  0.89%   
Neurocrine Biosciences Return On Capital Employed yearly trend continues to be fairly stable with very little volatility. Return On Capital Employed is likely to outpace its year average in 2025. During the period from 2010 to 2025, Neurocrine Biosciences Return On Capital Employed regression line of annual values had significance of  0.17 and arithmetic mean of  0.01. View All Fundamentals
 
Return On Capital Employed  
First Reported
2010-12-31
Previous Quarter
0.17767051
Current Value
0.19
Quarterly Volatility
0.23721993
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Neurocrine Biosciences financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Neurocrine Biosciences' main balance sheet or income statement drivers, such as Depreciation And Amortization of 28.5 M, Interest Expense of 132.9 M or Selling General Administrative of 1.1 B, as well as many indicators such as Price To Sales Ratio of 5.53, Dividend Yield of 0.0 or PTB Ratio of 6.06. Neurocrine financial statements analysis is a perfect complement when working with Neurocrine Biosciences Valuation or Volatility modules.
  
Build AI portfolio with Neurocrine Stock
Check out the analysis of Neurocrine Biosciences Correlation against competitors.
For more information on how to buy Neurocrine Stock please use our How to Invest in Neurocrine Biosciences guide.

Latest Neurocrine Biosciences' Return On Capital Employed Growth Pattern

Below is the plot of the Return On Capital Employed of Neurocrine Biosciences over the last few years. It is Neurocrine Biosciences' Return On Capital Employed historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Neurocrine Biosciences' overall financial position and show how it may be relating to other accounts over time.
Return On Capital Employed10 Years Trend
Slightly volatile
   Return On Capital Employed   
       Timeline  

Neurocrine Return On Capital Employed Regression Statistics

Arithmetic Mean0.01
Coefficient Of Variation1,752
Mean Deviation0.19
Median0.1
Standard Deviation0.24
Sample Variance0.06
Range0.8121
R-Value0.36
Mean Square Error0.05
R-Squared0.13
Significance0.17
Slope0.02
Total Sum of Squares0.84

Neurocrine Return On Capital Employed History

2025 0.19
2024 0.18
2023 0.0966
2022 0.14
2021 0.11
2020 0.21
2019 0.3

About Neurocrine Biosciences Financial Statements

Neurocrine Biosciences investors use historical fundamental indicators, such as Neurocrine Biosciences' Return On Capital Employed, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Neurocrine Biosciences. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Capital Employed 0.18  0.19 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Neurocrine Stock Analysis

When running Neurocrine Biosciences' price analysis, check to measure Neurocrine Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Neurocrine Biosciences is operating at the current time. Most of Neurocrine Biosciences' value examination focuses on studying past and present price action to predict the probability of Neurocrine Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Neurocrine Biosciences' price. Additionally, you may evaluate how the addition of Neurocrine Biosciences to your portfolios can decrease your overall portfolio volatility.